"Lipoproteins, LDL" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A class of lipoproteins of small size (18-25 nm) and light (1.019-1.063 g/ml) particles with a core composed mainly of CHOLESTEROL ESTERS and smaller amounts of TRIGLYCERIDES. The surface monolayer consists mostly of PHOSPHOLIPIDS, a single copy of APOLIPOPROTEIN B-100, and free cholesterol molecules. The main LDL function is to transport cholesterol and cholesterol esters to extrahepatic tissues.
| Descriptor ID |
D008077
|
| MeSH Number(s) |
D10.532.515 D12.776.521.550
|
| Concept/Terms |
Lipoproteins, LDL- Lipoproteins, LDL
- LDL Lipoproteins
- Low-Density Lipoproteins
- Lipoproteins, Low-Density
- Low Density Lipoproteins
- beta-Lipoproteins
- beta Lipoproteins
LDL-1- LDL-1
- LDL1
- Low-Density Lipoprotein 1
- Low Density Lipoprotein 1
- LDL(1)
LDL-2- LDL-2
- LDL2
- Low-Density Lipoprotein 2
- Low Density Lipoprotein 2
- LDL(2)
|
Below are MeSH descriptors whose meaning is more general than "Lipoproteins, LDL".
Below are MeSH descriptors whose meaning is more specific than "Lipoproteins, LDL".
This graph shows the total number of publications written about "Lipoproteins, LDL" by people in this website by year, and whether "Lipoproteins, LDL" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1998 | 0 | 1 | 1 |
| 2000 | 0 | 1 | 1 |
| 2003 | 1 | 1 | 2 |
| 2004 | 1 | 1 | 2 |
| 2005 | 2 | 0 | 2 |
| 2007 | 0 | 1 | 1 |
| 2009 | 2 | 1 | 3 |
| 2010 | 0 | 1 | 1 |
| 2012 | 1 | 1 | 2 |
| 2014 | 1 | 0 | 1 |
| 2015 | 1 | 1 | 2 |
| 2016 | 0 | 2 | 2 |
| 2017 | 12 | 12 | 24 |
| 2018 | 13 | 15 | 28 |
| 2019 | 5 | 5 | 10 |
To return to the timeline, click here.
Below are the most recent publications written about "Lipoproteins, LDL" by people in Profiles.
-
Mitigating the effects of COVID-19 pandemic on controlling vascular risk factors among participants in a carotid stenosis trial. J Stroke Cerebrovasc Dis. 2020 Dec; 29(12):105362.
-
Mevalonate pathway, selenoproteins, redox balance, immune system, Covid-19: Reasoning about connections. Med Hypotheses. 2020 Nov; 144:110128.
-
Role of oxidized LDL-induced "trained macrophages" in the pathogenesis of COVID-19 and benefits of pioglitazone: A hypothesis. Diabetes Metab Syndr. 2020 Jul - Aug; 14(4):713-714.
-
Why is hypercholesterolaemia so prevalent? A view from evolutionary medicine. Eur Heart J. 2019 09 01; 40(33):2825-2830.
-
Apolipoprotein B as a New Link Between Cholesterol and Alzheimer Disease. JAMA Neurol. 2019 07 01; 76(7):751-753.
-
Associations of growth from birth to puberty with blood pressure and lipid profile at ~17.5 years: evidence from Hong Kong's "Children of 1997" birth cohort. Hypertens Res. 2019 03; 42(3):419-427.
-
Long-term effect of pioglitazone vs glimepiride on lipoprotein oxidation in patients with type 2 diabetes: a prospective randomized study. Acta Diabetol. 2019 May; 56(5):505-513.
-
Oxidized LDL upregulates macrophage DPP4 expression via TLR4/TRIF/CD36 pathways. EBioMedicine. 2019 Mar; 41:50-61.
-
Untargeted Mass Spectrometry Lipidomics identifies correlation between serum sphingomyelins and plasma cholesterol. Lipids Health Dis. 2019 Feb 02; 18(1):38.
-
The DPP-4 inhibitor saxagliptin ameliorates ox-LDL-induced endothelial dysfunction by regulating AP-1 and NF-?B. Eur J Pharmacol. 2019 May 15; 851:186-193.